CytomX Therapeutics, Inc.

Good afternoon and welcome to the Cytomix 2018 Full Year Financial Results Conference Call. At this time, all participants are in a listen-only mode. Later, we will conduct a question-and-answer session and instructions will be given at that time. If anyone should require operator assistance during the conference, please press star then zero on your telephone keypad. Please be aware that today's conference call is being recorded. I'd now like to turn the call over to Chris Keenan, Cytomix's Vice President of Investor Relations. You may begin.

Good afternoon, and thank you for joining us for our 2018 Full-Year Financial Results Conference Call. Here with me today is CytomX President, Chief Executive Officer and Chairman, Dr. Sean McCarthy, and Debonjon Ray, our Chief Financial Officer. Before we begin, I would like to remind you that we will be making forward-looking statements during the call. Because forward-looking statements relate to the future, they are subject to inherent uncertainties and risks that are difficult to predict, and many of which are outside of our control. Important risks and uncertainties are set forth in our most recent public filings with the SEC at SEC.gov, including our Form 10-K filed today. We undertake no obligation to update any forward-looking statements, whether as a result of new information, future developments, or otherwise. A webcast of this call will be available on the Investor Relations page at Cytomix's website at Cytomix.com. I would now like to turn the call over to Sean.

Thanks, Chris, and good afternoon, everyone. I'm very pleased to be here with you today to review what has been a highly productive year for cytomics and also to outline what to look for in the year ahead. Over the past year, we've generated meaningful clinical proof-of-concept data for the ProBody platform across both of our lead wholly-owned programs as we've Presented at ASCO, ESMO, CITC, and also yesterday at our inaugural Research and Development Day held in New York. I refer you to the webcast from yesterday's event for a full update on our programs and pipeline. I would like to make a few brief comments here on our lead programs, CX072 and CX2009, on our PD1 probody, CX188, and also on our BMS Alliance. PD-L1 ProBody Therapeutics, CX072, is active across a range of tumor types and has a potentially differentiated safety profile as monotherapy and, importantly, in combination with other agents such as ipilimumab. CX2009, our first-in-class CD166 ProBody drug conjugate, is generally well-tolerated and has demonstrated anti-tumor activity across multiple tumor types. In 2019, we will continue to explore the full potential of these innovative product candidates as we maintain our intense focus on discovery, development, and ultimate commercialization of a new generation of differentiated cancer therapeutics. Regarding CX2009, we're encouraged by the Phase I safety and efficacy data that we presented yesterday that show that this is an active drug candidate across several tumor types, with intriguing anti-cancer activity in heavily pretreated patients. CD166 is a very novel target, and CX2009 has the potential to be a first-in-class targeted anti-cancer agent. Our next step for the program is to select the dose for further expansions into select tumor types, and additional work to this end is well underway. Regarding CX188, our PD1 probody, We recently decided to deprioritize this program, despite the fact the IMD was readily cleared by the FDA in Q4. We made this decision principally because of the ongoing success we're having with the anti-PDL1 probody CX072. We feel that capital allocation at this time to PD1, in addition to PDL1, is not the most efficient use of our resources, given the many other opportunities in our pipeline. Now turning to our BMS alliance, This partnership was first entered into in 2014 and was expanded in 2017. In total, the Alliance provides BMS with access to up to 12 discovery targets. The lead program in the Alliance, the anti-CTLA-4 probody, BMS 986249, continues to progress through a Phase I-II clinical trial being run by BMS. In conjunction with our broad R&D update yesterday, we announced that BMS has deprioritized three collaboration targets. This reflects the natural ebb and flow of a long-term, multi-target, discovery-stage biotech-farmer partnership. The collaboration remains in full force and effect, and we look forward to continuing to make progress on existing collaboration programs and future targets that BMS may select. Now with that, let me turn the call over to Dibhanjan for a review of financial results. I'll come back shortly after that for a look at the year ahead.